Clinical trials: COVID-19 Booster
COVID-19
Booster Study of SpikoGen COVID-19 Vaccine
The purpose of the study is to assess the effectiveness of Spikogen vaccine when used as a 3rd or 4th dose booster in adults who have been previously vaccinated with any Covid-19 vaccine types, including mRNA vaccine, adenoviral…
- Trial name
- NCT05542862
- Testing
- SpikoGen vaccine
- Where
- Australia
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- Vaxine Pty Ltd
SARS-CoV-2
A Study to Evaluate the Immunogenicity and Safety of Omicron Variant Vaccines in Comparison With mRNA-1273 Booster Vaccine for COVID-19
This is a 2-part study to evaluate the immunogenicity, safety, and reactogenicity of mRNA-1273.529 and mRNA-1273.214 administered as a booster dose.
- Trial name
- NCT05249829
- Testing
- mRNA-1273.529, mRNA-1273, mRNA-1273.214
- Where
- 29 sites in United Kingdom
- Volunteers
- 3,548 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
COVID-19
A Study to Investigate the Safety, Immunogenicity of Bivalent mRNA Vaccine RQ3027 and RQ3025 as a Booster Dose in Healthy Adults
This clinical trial aimed to gather safety and immunogenicity data in COVID-19 vaccine-experienced healthy adults. The main questions it aims to answer are: The neutralizing antibodies levels of bivalent mRNA vaccines…
- Trial name
- NCT05907044
- Testing
- RQ3013, RQ3025, RQ3027
- Where
- China
- Volunteers
- 376 people, healthy volunteers welcome
- Sponsor
- Affiliated Hospital of Yunnan University
Humoral Immunity
Humoral Immunity Study After a Booster Dose of Soberana Plus (FINLAY-FR-1A) Vaccine Against COVID-19
To evaluate the dynamics of IgG levels to the SARS-CoV-2 virus after a booster dose of Soberana Plus vaccine.
- Trial name
- NCT05689177
- Testing
- Protein subunit vaccine Soberana Plus (FINLAY-FR-1A) is a vaccine against COVID-19 produced by The Finlay Vaccine Institute and The Centre of Molecular Immunology (Republic of Cuba)
- Where
- Belarus
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Gomel State Medical University
Immunogenicity, Efficacy
New Generation mRNA Booster Vaccine Against Emerging VOCs
Primary：Objectives ：SafetyTo describe the safetyprofile of all participants in each group up to 6months post-dose.Immunogenicity：To demonstrate the superiorityof neutralizing antibodyresponse in terms of geometric mean titers…
- Conditions
- Immunogenicity, Efficacy, Safety
- Trial name
- NCT05580159
- Testing
- SW-BIC-213, SARS-Cov-2 Vaccina(Vero Cell ) Inactivated
- Where
- Laos
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Stemirna Therapeutics
COVID-19
A Phase I/II Study of GLB-COV2-043 as a COVID-19 Vaccine Booster
The scope of this Phase I/II study is to determine whether GLB-COV2-043 is a promising booster vaccine candidate component for adult participants who have received the 2-dose priming course of the mRNA BNT162b2 vaccine against…
- Trial name
- NCT05602961
- Testing
- GLB-COV2-043, BNT162b2/COMIRNATY®
- Volunteers
- healthy volunteers welcome
- Sponsor
- GreenLight Biosciences, Inc.
COVID 19, Influenza
COVID-19 Booster and IIV Schedule in Immunocompromised Hosts
The goal of this pragmatic embedded open-label, 2 x 2 factorial phase II randomized controlled trial is to evaluate strategies to improve COVID-19 booster and influenza vaccine immunogenicity in people living with…
- Conditions
- COVID 19, Influenza, Rheumatoid Arthritis (RA), Systemic Lupus Erthematosus
- Trial name
- CO2I2 (NCT06599658)
- Testing
- Inactivated influenza vaccine (IIV) at baseline, COVID-19 Vaccines at a 3-month interval, Inactivated influenza vaccine at Month 1
- Where
- 3 sites in Canada
- Volunteers
- 660 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
COVID-19 Respiratory Infection, COVID-19 Vaccine Adverse Reaction
A Randomized, Phase I Study of DNA Vaccine OC-007 as a Booster Dose of COVID-19 Vaccine
This is a randomized, placebo-controlled, double-blinded phase I study, designed to evaluate the safety including reactogenicity and immunogenicity of this investigational DNA vaccine delivered intramuscularly by in vivo EP in…
- Trial name
- OpenCorona1 (NCT05685953)
- Testing
- DNA vaccine OC-007
- Where
- Sweden
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Matti Sällberg
SARS-CoV-2 Infection
Phase II/III Study of the AVX/COVID-12 Vaccine Against COVID-19 Applied as a Booster.
This is a phase II/III parallel, double-blind, active-controlled, non-inferiority study to evaluate immunogenicity and safety of a booster immunization scheme of a single intramuscular dose of the recombinant vaccine against…
- Trial name
- NCT05710783
- Testing
- AVX-COVID/12, ChAdOx-1-S[recombinant]
- Where
- 14 sites in Mexico
- Volunteers
- 4,065 people, healthy volunteers welcome
- Sponsor
- Laboratorio Avi-Mex, S.A. de C.V.
Rheumatoid Arthritis, Autoimmune Rheumatologic Disease
COvid-19 Vaccine Booster in Immunocompromised Rheumatic Diseases
People living with Systemic autoimmune rheumatic diseases (SARDs) face a new and urgent dilemma: immunosuppression increases risk for worse COVID-19 infection, yet an immune stimulation, such as vaccination, could re-activate…
- Conditions
- Rheumatoid Arthritis, Autoimmune Rheumatologic Disease, Systemic Lupus Erythematosus, Systemic Vasculitis
- Trial name
- COVBIRD (NCT05236491)
- Testing
- COVID-19 vaccine
- Where
- 2 sites in Canada
- Volunteers
- 287 people
- Sponsor
- Paul R Fortin
Severe Acute Respiratory Syndrome Coronavirus 2 Infection
A Clinical Trial to Study the COVAC-1 Booster Dose in Generally Healthy Adults
VIDO has developed a vaccine called COVAC-1. The COVAC-1 study vaccine contains a portion of the SARS-CoV-2 spike protein, called S1.
- Trial name
- NCT05693272
- Testing
- COVAC-1
- Where
- 4 sites in Canada
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- University of Saskatchewan
COVID-19
Immunogenicity and Safety Study of the 3rd Booster Dose Using the High or Medium Dose of Inactivated (CoronaVac®) Vaccine in Healthy Adults in Turkey
This is a randomized, double-blinded, and positive-controlled Phase IIb clinical trial of COVID-19 vaccine (CoronaVac®) manufactured by Sinovac Research \& Development Co., Ltd.The purpose of this study is to evaluate the…
- Trial name
- NCT05150496
- Testing
- Medium-dose COVID-19 Vaccine(Vero Cell),Inactivated, High-dose COVID-19 Vaccine(Vero Cell),Inactivated
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 640 people, healthy volunteers welcome
- Sponsor
- Sinovac Research and Development Co., Ltd.
COVID-19 (Healthy Volunteers)
Safety, Reactogenicity, and Immunogenicity Study of Heterologous Booster Vaccination of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510)
This is randomized, placebo-controlled, observer-blinded, multi-center study to assess safety, reactogenicity and immunogenicity of booster vaccination of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted…
- Trial name
- NCT05175950
- Testing
- SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510) (RBD of SARS-CoV-2 25ug / dose) Adjuvanted with AS03, Normal saline
- Where
- 9 sites in South Korea
- Volunteers
- 770 people, healthy volunteers welcome
- Sponsor
- Korea University Guro Hospital
Multiple Sclerosis
COVID-19 Booster Vaccination in Persons With Multiple Sclerosis
The success of the U.S. vaccination program against SARS-Cov-2 is shown by a dramatic drop in infection rates, hospitalizations and deaths.However, it appears that many persons who take medications that chronically suppress the…
- Trial name
- NCT05081271
- Testing
- Homologous booster, Heterologous booster
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Griffin Hospital
COVID-19, COVID-19 Vaccines
COVID-19 Quantitative Antibody Titers & Booster Vaccinations
This is an observational study aiming at describing COVID-19 vaccination outcomes among HIV-positive and HIV-negative individuals, using electronic health records to observe their usual clinical care.
- Conditions
- COVID-19, COVID-19 Vaccines, Immunogenicity, Vaccine
- Trial name
- NCT05104359
- Testing
- Observational
- Where
- United States
- Volunteers
- 825 people
- Sponsor
- Epividian
COVID-19
Immunogenicity and Safety of Booster Immunization of ZF2001 After Inoculation With Two Doses of CoronaVac
Study objectives: To evaluate the immunogenicity and immunity persistence and safety of recombinant novel coronavirus vaccine (CHO cells) after booster immunization in populations vaccinated with two doses of marketed novel…
- Trial name
- NCT05205096
- Testing
- Recombinant novel coronavirus vaccine (CHO cells)
- Where
- China
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
COVID-19
A Study of Booster Immunization With COVID-19 Vaccine,Inactivated Co -Administration With Influenza Vaccine and Pneumococcal Polysaccharide Vaccine
This study is a single center , randomized ,controlled and open-label phase Ⅳclinical trial of the booster immunization with the third dose of inactivated COVID-19 vaccine(CoronaVac)manufactured by Sinovac Research \& Development…
- Trial name
- NCT05499351
- Testing
- Adult group in immunogenicity and safety study of combined immunization, Elderly group in immunogenicity and safety study of combined immunization, Adult group in safety observation study of combined immunization
- Where
- China
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
SARS-CoV-2 Infection
Booster Superiority Study of PTX-COVID19-B Compared to Vaxzevria® in Adults Aged 18 Years and Older
This is a Phase III, Randomized, Observer-Blind Study to Evaluate the Safety and Superiority in Immunogenicity of PTX-COVID19-B Administered as Booster Vaccination Compared to Vaxzevria® in Adults Aged 18 Years and Older Who Were…
- Trial name
- NCT05534035
- Testing
- PTX-COVID19-B, Vaxzevria®
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Everest Medicines (Singapore) Pte. Ltd.
COVID-19, Vaccine-Preventable Diseases
The Efficacy of the 2023-2024 Updated COVID-19 Vaccines Against COVID-19 Infection
The purpose of this research study is to find out how well two different 2023-2024 updated COVID-19 vaccines protect people from COVID-19 (the disease caused by the SARS-CoV-2 virus), and to determine if getting a 2023-2024…
- Conditions
- COVID-19, Vaccine-Preventable Diseases, SARS CoV 2 Infection, Upper Respiratory Tract Infection
- Trial name
- BEEHIVE (NCT06065176)
- Testing
- Novavax COVID-19 vaccine (2023-2024 formula XBB containing), Pfizer COVID-19 mRNA vaccine (2023-2024 formula XBB containing)
- Where
- United States
- Volunteers
- 1,188 people, healthy volunteers welcome
- Sponsor
- Sarang K. Yoon, DO, MOH
COVID-19
Evaluate the Safety and Immunogenicity of Ad5 COVID-19 Vaccines for Booster Use in Children Aged 6-17 Years.
This is a single center, open-label, parallel controlled, and randomized Phase II clinical trial to evaluate the safety and immunogenicity of two types of Recombinant Novel Corona Virus Vaccine (Adenovirus type 5 vector) in…
- Trial name
- NCT05330871
- Testing
- 1 Nebulized inhalation for booster groups, 2 Nebulized inhalation for booster groups, 3 Nebulized inhalation for booster groups
- Where
- China
- Volunteers
- 410 people, healthy volunteers welcome
- Sponsor
- Seventh Medical Center of PLA General Hospital